Skip to main content

Advertisement

Log in

Remission in Juvenile Idiopathic Arthritis: Current Facts

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory arthritic disease affecting children. Despite the availability of potent disease-modifying antirheumatic medications, most children still experience a chronic course with long periods of active disease. Goals of treatment should include achievement of disease remission with optimal physical functioning that allows children to lead normal lives with no structural joint damage. The term remission implies a complete lack of disease activity. This article focuses on recently developed preliminary criteria for inactive disease and remission in JIA. Recent studies using these new definitions demonstrate only modest rates of achievement of remission favoring children with persistent oligoarticular JIA. Children with rheumatoid factor-positive polyarticular JIA are least likely to achieve remission. Therapeutic strategies to achieve remission are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently have been highlighted as: • Of importance •• Of major importance

  1. Packham JC, Hall MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002, 41:1428–1435.

    Article  CAS  Google Scholar 

  2. Zak M, Pedersen FK: Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford) 2000, 39:198–204.

    Article  CAS  Google Scholar 

  3. Wallace CA, Levinson JE: Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991, 17:891–905.

    CAS  PubMed  Google Scholar 

  4. Minden K, Kiessling U, Listing J, et al.: Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 2000, 27:2256–2263.

    CAS  PubMed  Google Scholar 

  5. Oen K, Malleson PN, Cabral DA, et al.: Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002, 29:1989–1999.

    PubMed  Google Scholar 

  6. Woo P: Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders. Curr Opin Rheumatol 2009, 21:552–557.

    Article  CAS  PubMed  Google Scholar 

  7. • Bartoli M, Taro M, Magni-Manzoni S, et al.: The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:370–374. This study demonstrated that favorable response to methotrexate in JIA helps predict improved long-term outcome.

    Article  CAS  PubMed  Google Scholar 

  8. van Rossum MA, van Soesbergen RM, Boers M, et al.: Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007, 66:1518–1524.

    Article  PubMed  Google Scholar 

  9. Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308–1315.

    Article  CAS  PubMed  Google Scholar 

  10. van Gestel AM, Prevoo ML, van ’t Hof MA, et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34–40.

    Article  PubMed  Google Scholar 

  11. van der Heijde DM, van ’t Hof MA, van Riel PL, et al.: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990, 49:916–920.

    Article  PubMed  Google Scholar 

  12. van der Heijde DM, van ’t Hof MA, van Riel PL, et al.: Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992, 51:177–181.

    Article  PubMed  Google Scholar 

  13. Prevoo ML, van ’t Hof MA, Kuper HH, et al.: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44–48.

    Article  CAS  PubMed  Google Scholar 

  14. Saleem B, Nizam S, Emery P: Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006, 24(6 Suppl 43):S33–S36.

    Google Scholar 

  15. Smolen JS, Aletaha D: What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006, 24(6 Suppl 43):S7–S13.

    Google Scholar 

  16. Pincus T, Kavanaugh A, Aletaha D, Smolen J: Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol 2006, 24(6 Suppl 43):S1–S6.

    Google Scholar 

  17. Sesin CA, Bingham CO 3rd: Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2005, 35:185–196.

    Article  PubMed  Google Scholar 

  18. Makinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005, 64:1410–1413.

    Article  CAS  PubMed  Google Scholar 

  19. Molenaar ET, Voskuyl AE, Dinant HJ, et al.: Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004, 50:36–42.

    Article  PubMed  Google Scholar 

  20. Prevoo ML, van Gestel AM, van ’t Hof MA, et al.: Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996, 35:1101–1105.

    Article  CAS  PubMed  Google Scholar 

  21. Fransen J, Creemers MC, Van Riel PL: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004, 43:1252–1255.

    Article  CAS  Google Scholar 

  22. Mierau M, Schoels M, Gonda G, et al.: Assessing remission in clinical practice. Rheumatology (Oxford) 2007, 46:975–979.

    Article  CAS  Google Scholar 

  23. van Tuyl LH, Vlad SC, Felson DT, et al.: Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009, 61:704–710.

    Article  PubMed  Google Scholar 

  24. •• Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31:2290–2294. Original article, documenting preliminary criteria for remission in JIA.

    PubMed  Google Scholar 

  25. • Wallace CA, Ravelli A, Huang B, Giannini EH: Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006, 33:789–795. Original study for validation of remission criteria in JIA.

    PubMed  Google Scholar 

  26. • Wallace CA, Huang B, Bandeira M, et al.: Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:3554–3562. Retrospective study of JIA patients showing time spent in disease activity states.

    Article  PubMed  Google Scholar 

  27. Lurati A, Salmaso A, Gerloni V, et al.: Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases. J Rheumatol 2009, 36:1532–1535.

    Article  PubMed  Google Scholar 

  28. Fernandes TA, Corrente JE, Magalhaes CS: Remission status follow-up in children with juvenile idiopathic arthritis. J Pediatr (Rio J) 2007, 83:141–148.

    Google Scholar 

  29. Ringold S, Seidel KD, Koepsell TD, Wallace CA: Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009, 48:972–977.

    Article  Google Scholar 

  30. Russo RA, Katsicas MM: Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009, 36:1078–1082.

    Article  CAS  PubMed  Google Scholar 

  31. Solari N, Viola S, Pistorio A, et al.: Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum 2008, 59:1571–1579.

    Article  PubMed  Google Scholar 

  32. Magni-Manzoni S, Ruperto N, Pistorio A, et al.: Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008, 59:1120–1127.

    Article  PubMed  Google Scholar 

  33. • Foell D, Wulffraat N, Wedderburn LR, et al.: Towards a risk-adapted therapy to maintain clinical remission in juvenile idiopathic arthritis: results of a randomized trial of 6 versus 12 months withdrawal of methotrexate. [abstract 551]. Presented at the American College of Rheumatology Annual Meeting. Philadelphia, PA; October 16–21, 2009. This study looked at duration of methotrexate therapy in ID to determine the risk of relapse. The study also used myeloid-related proteins as a biologic marker to determine the risk for flare in JIA.

  34. • Tynjala P, Vahasalo P, Tarkisinen M, et al.: Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (A-CUTE-JIA): a multicenter randomized clinical trial. [abstract 2051]. Presented at the American College of Rheumatology Annual Meeting. Philadelphia, PA; October 16–21, 2009. This abstract showed preliminary results from the A-CUTE-JIA, a study that compared three different treatment regimens used for JIA.

  35. Knowlton N, Jiang K, Frank MB, et al.: The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum 2009, 60:892–900.

    Article  CAS  PubMed  Google Scholar 

  36. Prelog M, Schwarzenbrunner N, Tengg E, et al.: Quantitative alterations of CD8+ T cells in juvenile idiopathic arthritis patients in remission. Clin Rheumatol 2009, 28:385–389.

    Article  PubMed  Google Scholar 

  37. • Magnani A, Pistorio A, Magni-Manzoni S, et al.: Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol 2009, 36:628–634. This study showed that children with JIA who attain ID early on in their disease course tend to have less long-term joint damage.

    Article  PubMed  Google Scholar 

  38. Beukelman T, Guevara JP, Albert DA: Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008, 59:1580–1588.

    Article  PubMed  Google Scholar 

  39. Ruperto N, Murray KJ, Gerloni V, et al.: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004, 50:2191–2201.

    Article  CAS  PubMed  Google Scholar 

  40. Wallace CA: The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998, 41:381–391.

    Article  CAS  PubMed  Google Scholar 

  41. Wallace CA, Sherry DD, Mellins ED, Aiken RP: Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993, 20:118–122.

    CAS  PubMed  Google Scholar 

  42. Klein A, Horneff G: Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009, 10:3049–3060.

    Article  CAS  PubMed  Google Scholar 

  43. Beresford MW, Baildam EM: New advances in the management of juvenile idiopathic arthritis—2. The era of biologicals. Arch Dis Child Educ Pract Ed 2009, 94:151–156.

    Article  CAS  PubMed  Google Scholar 

  44. Hayward K, Wallace CA: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009, 11:216.

    Article  PubMed  CAS  Google Scholar 

  45. Shenoi S, Wallace CA: TNF alpha inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 2010 (in press).

  46. Quinn MA, Conaghan PG, O’Connor PJ, et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a 12-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27–35.

    Article  CAS  PubMed  Google Scholar 

  47. Boers M: Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003, 48:1771–1774.

    Article  PubMed  Google Scholar 

  48. Moreland LW, Bridges SL Jr: Early rheumatoid arthritis: a medical emergency? Am J Med 2001, 111:498–500.

    Article  CAS  PubMed  Google Scholar 

  49. O’Dell JR: Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002, 46:283–285.

    Article  PubMed  Google Scholar 

  50. Breedveld FC, Emery P, Keystone E, et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149–155.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carol A. Wallace.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shenoi, S., Wallace, C.A. Remission in Juvenile Idiopathic Arthritis: Current Facts. Curr Rheumatol Rep 12, 80–86 (2010). https://doi.org/10.1007/s11926-010-0085-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-010-0085-2

Keywords

Navigation